Article info
PDFCorrespondence
Correspondence on ‘Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?’
- Correspondence to Dr Socrates Angelides, Nuclear Medicine, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia; Socrates.Angelides{at}health.nsw.gov.au
Citation
Correspondence on ‘Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?’
Publication history
- Received December 12, 2020
- Accepted December 15, 2020
- First published January 27, 2021.
Online issue publication
October 18, 2023
Article Versions
- Previous version (18 October 2023).
- Previous version (18 October 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.